Abstract:Background and objective: An orodispersible tablet (ODT) formulation of morphine sulfate has been developed to provide a novel alternative for patients with severe pain requiring opioids. This formulation has been developed in a range of doses (1-30 mg), enabling relief from severe pain to be achieved and maintained with the lowest possible morphine dose for each patient. The ODT formulation is particularly suitable for patients with swallowing difficulties. Objective: The aim of this study was to compare the pharmacokinetics and bioequivalence of the ODTs with reference formulations of morphine sulfate. Methods: Three randomized, single-dose, laboratory-blinded, phase I, crossover studies were conducted in adult healthy volunteers under fasting conditions. The pharmacokinetics of a 30 mg morphine sulfate ODT were compared with those of equivalent doses of currently marketed oral immediate-release formulations: tablets (Sevredol®), capsules (Actiskenan®), and a solution (Oramorph®). The bioequivalence of 30 mg and 10 mg doses of the ODTs and tablets was then assessed in two further studies. Subjects were asked to complete a product appreciation questionnaire for two morphine formulations (ODT and solution). Results: A total of 104 subjects were included across the three studies. The pharmacokinetics of the ODTs were assessed in 100 subjects and were found to be similar to those of the reference formulations. The time to maximum plasma concentration (Tmax) for the ODTs was 0.8 h, within the range observed for the reference formulations (0.75-1.25 h). Maximum plasma concentrations (Cmax) for the ODTs were 7.7 ± 2.7 ng/mL for the 10 mg dose and 26.1 ± 10.0 ng/mL for the 30 mg dose. These values were similar to those obtained for the 10 mg and 30 mg tablets (8.0 ± 2.9 ng/mL and 28.5 ± 11.9 ng/mL, respectively), and for the 30 mg capsule (29.9 ± 13.0 ng/mL). A higher Cmax was observed for the solution (37.9 ± 16.5 ng/mL). Plasma exposure to morphine (area under the plasma drug concentration-time curve [AUC]) after ODT administration was similar to that observed for the reference formulations: 39.8 ± 14.8 ng·h/mL and 115.5 ± 34.6 ng·h/mL for the 10 mg and 30 mg ODTs, versus 40.7 ± 13.5 ng·h/mL and 117.4 ± 31.5 ng·h/mL for the 10 mg and 30 mg tablets, and 121.8 ± 32.0 ng·h/mL and 121.0 ± 35.7 ng·h/mL for the 30 mg solution and capsule, respectively. Bioequivalence of the 30 mg and 10 mg ODTs and tablets, assessed in 83 patients across two studies, was demonstrated for both the Cmax and AUC from time zero to time t (AUC0-t). No serious or unexpected drug-related events were reported. A product appreciation questionnaire concluded that both ODTs and oral solution products were considered pleasant by most of the subjects. Conclusion: The ODTs were safe, well tolerated, and showed similar pharmacokinetics to those of the reference formulations. The development of a range of doses of morphine sulfate ODTs may provide a new alternative for the oral administration of immediate-release morphine for pain management in pediatric, geriatric and adult populations with swallowing problems.

Investigation on Use of Oral Sustained-Release Tablets or Enteric-Coated Tablets in Hospitalized Children from a Children's Hospital in Shanghai

Effect of Omeprazole in treating peptic ulcers of children

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Development and Optimization of Sildenafil Orodispersible Mini-Tablets (ODMTs) for Treatment of Pediatric Pulmonary Hypertension Using Response Surface Methodology

Real-world data for the availability of pediatric medicines in Chinese hospitals: a multi-center survey and analysis

The dose titration efficacy studies of methylphenidate hydrochloride controlled-release tablets in the treatment of attention deficit hyperactivity disorder with conduct disorder in children.

Survey-based investigation into the current use of paediatric medicines and administration devices in China

Analysis of Outpatient Off-label Use in the Third Hospital of Peking University

Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Questionnaire Study to Investigate the Preferences of Children, Parents, and Healthcare Professionals for Different Formulations of Oral Medicinal Products

Single Dose and Dosage Frequency of Analgesic Drugs in 9 Chinese Cancer Hospitals in 2012

The Characteristic and Difference of Drugs Use between Outpatients and Inpatients of Pediatrics and Rationality Analysis in a Grade Three Hospital

The exploration on criteria and compromise in the prescription review of Chinese patent medicines X: medication for children

Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics

Current Status of Pediatric Labeling in China and the Near Future Efforts Needed for the Country.

[Survey on Common Pediatric Drugs for Renal Diseases].

Comparison and Analysis on Instructions for Foreign and Domestic Aspirin Enteric-coated Tablets

[Research progress and innovation of drug delivery devices based on children's multidimensional demand for medication]

Current practice, management and awareness of pediatric off-label drug use in China-A questionnaire based cross-sectional survey

Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children